SARS-CoV-2 NP ORF Mammalian Expression 

To Order Contact us: stephen@expresspharmapulse.com

SARS CoV-2 PCR kit
PCR-H731-96R 96T
EUR 1113

Anti-SARS-CoV-2 Antibody
A2061-50 50 µg
EUR 480

SARS-CoV-2 Spike Peptide
9083P 0.05 mg
EUR 196.25
Description: (NT) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide
9087P 0.05 mg
EUR 196.25
Description: (CT) SARS-CoV-2 Spike RBD peptide

SARS-CoV-2 Spike Peptide
9091P 0.05 mg
EUR 196.25
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide
9095P 0.05 mg
EUR 196.25
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Nucleocapsid Peptide
9099P 0.05 mg
EUR 196.25
Description: (IN) SARS-CoV-2 Nucleocapsid peptide

SARS-CoV-2 Nucleocapsid Peptide
9103P 0.05 mg
EUR 196.25
Description: (CT) SARS-CoV-2 Nucleocapsid peptide

SARS-CoV-2 Antigen ELISA Kit
DEIA2020 96 tests
EUR 905
Description: SARS-CoV-2 Antigen ELISA Kit intended use is for quantitative detection of the recombinant SARS-COV-2 nucleoprotein antigen in human serum. The use of this kit for natural samples need to be validated by the end user due to the complexity of natural targets and unpredictable interference.

SARS CoV-2 RT PCR kit
RTq-H731-100R 100T
EUR 1311

SARS CoV-2 RT PCR kit
RTq-H731-150R 150T
EUR 1787

SARS CoV-2 RT PCR kit
RTq-H731-50R 50T
EUR 963

SARS-CoV-2 IgG ELISA Kit
E4901-100 100 assays
EUR 753

Recombinant Coronavirus Nucleoprotein (SARS-CoV-2)
P1523-10 10 µg
EUR 156

Recombinant Coronavirus Nucleoprotein (SARS-CoV-2)
P1523-50 50 µg
EUR 551

SARS-CoV-2 Spike S2 Peptide
9119P 0.05 mg
EUR 196.25
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike S2 Peptide
9123P 0.05 mg
EUR 196.25
Description: (CT) SARS-CoV-2 Spike peptide

Anti-CoV-2 & SARS-CoV S1 Antibody (Clone# CR3022)
A2103-200 200 µg
EUR 480

SARS CoV E Protein
abx060650-1mg 1 mg
EUR 1692

SARS CoV Nucleocapsid Protein
abx060652-1mg 1 mg
EUR 1873

SARS-CoV Nucleocapsid Protein
abx060653-1mg 1 mg
EUR 1692

SARS-CoV Nucleocapsid Protein
abx060654-1mg 1 mg
EUR 1692

SARS-CoV Spike Protein
abx060655-1mg 1 mg
EUR 1692

SARS-CoV Spike Antibody
3219-002mg 0.02 mg
EUR 171.82
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3219-01mg 0.1 mg
EUR 436.42
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3221-002mg 0.02 mg
EUR 171.82
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3221-01mg 0.1 mg
EUR 436.42
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3223-002mg 0.02 mg
EUR 171.82
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3223-01mg 0.1 mg
EUR 436.42
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3225-002mg 0.02 mg
EUR 171.82
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody
3225-01mg 0.1 mg
EUR 436.42
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Matrix Antibody
3527-002mg 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody
3527-01mg 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody
3529-002mg 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Matrix Antibody
3529-01mg 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).

SARS-CoV Envelope Antibody
3533-002mg 0.02 mg
EUR 171.82
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

SARS-CoV Envelope Antibody
3533-01mg 0.1 mg
EUR 436.42
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

anti-MERS-CoV NP (2C11)
AR12-MA0010 100 ul
EUR 334
Description: Mouse monoclonal to MERS-CoV NP

anti-MERS-Cov NP (2D2)
AR12-MA0011 100 ul
EUR 334
Description: Mouse monoclonal to MERS-CoV NP

SARS CoV-2 One-Step PCR kit
Oneq-H731-100R 100T
EUR 1610

SARS CoV-2 One-Step PCR kit
Oneq-H731-150R 150T
EUR 2205

SARS CoV-2 One-Step PCR kit
Oneq-H731-50R 50T
EUR 1175

Anti-SARS-CoV-2 Antibody (Clone# 6F10)
A2060-50 50 µg
EUR 480

Anti-SARS-CoV-2 Spike S1 Antibody
A3000-50 50 µg
EUR 419

Coronavirus (SARS-CoV-2) PCR Detection Kit
K1460 100 Rxns
EUR 570
Description: Kit for detection of SARS-CoV-2 in respiratory specimens using Real-Time (RT-PCR).

Coronavirus (SARS-CoV-2) PCR Detection Kit
K1460-100 100 Rxns
EUR 551

Recombinant SARS-CoV-2 Nucleoprotein (1-430)
P1537-10 10 µg
EUR 156

Recombinant SARS-CoV-2 Nucleoprotein (1-430)
P1537-50 50 µg
EUR 530

Recombinant SARS-CoV-2 Nucleoprotein (1-430)
P1539-10 10 µg
EUR 156

Recombinant SARS-CoV-2 Nucleoprotein (1-430)
P1539-50 50 µg
EUR 530

Recombinant SARS-CoV-2 3C-like Proteinase
P1550-10 10 μg
EUR 156

Recombinant SARS-CoV-2 3C-like Proteinase
P1550-50 50 μg
EUR 551

Recombinant SARS-CoV-2 Papain-like Protease
P1551-10 10 μg
EUR 156

Recombinant SARS-CoV-2 Papain-like Protease
P1551-50 50 μg
EUR 551

SARS-CoV-2 Antigen Rapid Test Kit
CoV2Ag-1 1T
EUR 8
Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again.

SARS-CoV-2 Antigen Rapid Test Kit
CoV2Ag-25 25T/kit
EUR 35
Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection.

SARS-CoV-2 Rapid Antigen Test Nasal
9901-NCOV-03G 25 Tests/Kit
EUR 94
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

SARS-CoV-2 (COVID-19) Spike Antibody
3525-002mg 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike Antibody
3525-01mg 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Envelope Antibody
3531-002mg 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) Envelope Antibody
3531-01mg 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) NSP7 Peptide
9155P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP7 Peptide

SARS-CoV-2 (COVID-19) Membrane Peptide
9157P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) NSP8 Peptide
9159P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide

SARS-CoV-2 (COVID-19) NSP9 Peptide
9161P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide

SARS-CoV-2 (COVID-19) NSP9 Peptide
9163P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide

SARS-CoV-2 (COVID-19) Membrane Peptide
9165P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) NSP8 Peptide
9167P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide

SARS-CoV-2 (COVID-19) Envelope Peptide
9169P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Envelope Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide
9171P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide
9173P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP4 Peptide
9175P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide

SARS-CoV-2 (COVID-19) NSP6 Peptide
9177P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP6 Peptide

SARS-CoV-2 (COVID-19) NSP10 Peptide
9179P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP10 Peptide

SARS-CoV-2 (COVID-19) ORF6 Peptide
9189P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF6 Peptide

SARS-CoV-2 (COVID-19) ORF9b Peptide
9191P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF9b Peptide

SARS-CoV-2 (COVID-19) ORF3a Peptide
9275P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3a Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide
9277P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide
9279P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide
9281P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide

SARS-CoV-2 (COVID-19) ORF7a Peptide
9283P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide

SARS-CoV-2 (COVID-19) ORF7a Peptide
9285P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide

SARS-CoV-2 (COVID-19) ORF8 Peptide
9287P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide

SARS-CoV-2 (COVID-19) ORF8 Peptide
9289P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide

SARS-CoV-2 (COVID-19) ORF9c Peptide
9291P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF9c Peptide

SARS-CoV-2 (COVID-19) ORF10 Peptide
9293P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF10 Peptide

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
9099-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
9099-01mg 0.1 mg
EUR 495.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
9103-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody
9103-01mg 0.1 mg
EUR 495.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).

SARS-CoV-2 (COVID-19) NSP7 Antibody
9155-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers.

SARS-CoV-2 (COVID-19) NSP7 Antibody
9155-01mg 0.1 mg
EUR 495.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers.

SARS-CoV-2 NP ORF Mammalian Expression